A Tiny Biotech Says Its Ebola Drug Beat Remdesivir in the Lab
The result comes from cell-based tests and a single AI design cycle. The company says it will fund what comes next through government grants rather than new shares — and that an approved drug could carry a voucher worth up to $180 million.